McMahon was critical of the thousands of hours Lowey Dannenberg and other firms including Bernstein Liebhard and Cohen Milstein spent reviewing documents.
"This is the first time in the history of drug development that a compound has been tested first for prevention and then for treatment, " Dannenberg says.